Organogenesis Holdings Inc. reports third quarter net product revenue of $150.5 million

Reuters

11/07

<a href="https://laohu8.com/S/ORGO">Organogenesis Holdings Inc</a>. reports third quarter net product revenue of $150.5 million

Organogenesis Holdings Inc. reported third quarter 2025 net product revenue of $150.5 million, a 30.6% increase from $115.2 million in the same period of 2024. Net product revenue from Advanced Wound Care products reached $141.5 million, up 31% year over year. Net income for the quarter ranged between $8.6 million and $25.4 million, while adjusted net income was between $21.5 million and $38.4 million. EBITDA was between $19.1 million and $41.9 million, and adjusted EBITDA ranged from $45.5 million to $68.3 million. The company attributed the record revenue to execution of its strategy and highlighted positioning for 2026 in light of the new CMS payment rule and the potential of its ReNu product in a new market opportunity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organogenesis Holdings Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2581048698"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581048698\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581048698?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581048698","market":"us","top_or_hot":-1,"title":"Organogenesis Holdings Inc. reports third quarter net product revenue of $150.5 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ORGO\">Organogenesis Holdings Inc</a>. reports third quarter net product revenue of $150.5 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Organogenesis Holdings Inc. reported third quarter 2025 net product revenue of $150.5 million, a 30.6% increase from $115.2 million in the same period of 2024. Net product revenue from Advanced Wound Care products reached $141.5 million, up 31% year over year. Net income for the quarter ranged between $8.6 million and $25.4 million, while adjusted net income was between $21.5 million and $38.4 million. EBITDA was between $19.1 million and $41.9 million, and adjusted EBITDA ranged from $45.5 million to $68.3 million. The company attributed the record revenue to execution of its strategy and highlighted positioning for 2026 in light of the new CMS payment rule and the potential of its ReNu product in a new market opportunity.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organogenesis Holdings Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Organogenesis Holdings Inc. reports third quarter net product revenue of $150.5 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrganogenesis Holdings Inc. reports third quarter net product revenue of $150.5 million\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-07 05:17</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ORGO\">Organogenesis Holdings Inc</a>. reports third quarter net product revenue of $150.5 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Organogenesis Holdings Inc. reported third quarter 2025 net product revenue of $150.5 million, a 30.6% increase from $115.2 million in the same period of 2024. Net product revenue from Advanced Wound Care products reached $141.5 million, up 31% year over year. Net income for the quarter ranged between $8.6 million and $25.4 million, while adjusted net income was between $21.5 million and $38.4 million. EBITDA was between $19.1 million and $41.9 million, and adjusted EBITDA ranged from $45.5 million to $68.3 million. The company attributed the record revenue to execution of its strategy and highlighted positioning for 2026 in light of the new CMS payment rule and the potential of its ReNu product in a new market opportunity.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organogenesis Holdings Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ORGO","symbol_name":"Organogenesis Holdings Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL4rVz6n:1","article_id":"2581048698","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581048698","pubTimestamp":1762463836,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Organogenesis Holdings Inc. reported third quarter 2025 net product revenue of $150.5 million, a 30.6% increase from $115.2 million in the same period of 2024. Net product revenue from Advanced Wound Care products reached $141.5 million, up 31% year over year. Net income for the quarter ranged between $8.6 million and $25.4 million, while adjusted net income was between $21.5 million and $38.4 million. EBITDA was between $19.1 million and $41.9 million, and adjusted EBITDA ranged from $45.5 million to $68.3 million. The company attributed the record revenue to execution of its strategy and highlighted positioning for 2026 in light of the new CMS payment rule and the potential of its ReNu product in a new market opportunity.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fina","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ORGO":"Organogenesis Holdings Inc","BK4139":"生物科技"},"translate_title":"Organogenesis Holdings Inc.报告第三季度产品净收入为1.505亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ORGO":0.9},"content_text":"Organogenesis Holdings Inc. reports third quarter net product revenue of $150.5 million\n    \n\n        Organogenesis Holdings Inc. reported third quarter 2025 net product revenue of $150.5 million, a 30.6% increase from $115.2 million in the same period of 2024. Net product revenue from Advanced Wound Care products reached $141.5 million, up 31% year over year. Net income for the quarter ranged between $8.6 million and $25.4 million, while adjusted net income was between $21.5 million and $38.4 million. EBITDA was between $19.1 million and $41.9 million, and adjusted EBITDA ranged from $45.5 million to $68.3 million. The company attributed the record revenue to execution of its strategy and highlighted positioning for 2026 in light of the new CMS payment rule and the potential of its ReNu product in a new market opportunity.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organogenesis Holdings Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}